Department of Urology, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Department of General Surgery, the Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Eur J Pharmacol. 2017 Nov 15;815:495-500. doi: 10.1016/j.ejphar.2017.10.017. Epub 2017 Oct 12.
To investigate the detrusor fibrosis and urinary dysfunction in chronic prostatitis (CP), and to investigate whether resveratrol can improve the urinary dysfunction and the underlying molecular mechanism. After rat model of CP is established by subcutaneously injecting DPT vaccine, rats are treated with resveratrol. Experiments of bladder pressure and volume test in rats are used to investigate the effect of resveratrol on urinary dysfunction in CP rats. To assess tissue fibrosis, picrosirius red staining is performed. H&E staining is performed to identify the histopathological changes. Western blot and immunohistochemical staining are used to examine the expression of c-kit, SCF,tryptase, TGF-β, Wnt and α-SMA. The results of bladder pressure and volume test show that the maximum capacity of the bladder, residual urine volume and maximum voiding are increased significantly in CP rats. CP rats show significantly increased collagen deposition in the detrusor. H&E staining show that detrusor muscle arranged in disorder with fracture from CP rats. The results of western blot and immunohistochemical staining demonstrate that the activity of c-kit/SCF and TGF-β/Wnt/β-catenin pathway, expression levels of tryptase and α-SMA in bladder detrusor of CP group are significantly increased compared with the control group. However, resveratrol treatment significantly improved these factors. mast cell activation induced by the increased expression of c-kit/SCF in CP rats, may promote detrusor fibrosis which have a close relationship with urinary dysfunction. Resveratrol can improve the dysfunction by downregulating the mast cell activation and the activity of TGF-β/Wnt/β-catenin pathway.
为了研究慢性前列腺炎(CP)中逼尿肌纤维化和尿功能障碍,并研究白藜芦醇是否能改善尿功能障碍及其潜在的分子机制。通过皮下注射 DPT 疫苗建立 CP 大鼠模型后,用白藜芦醇进行治疗。使用大鼠膀胱压力和容量试验实验来研究白藜芦醇对 CP 大鼠尿功能障碍的影响。为了评估组织纤维化,进行苦味酸天狼星红染色。进行 H&E 染色以识别组织病理学变化。使用 Western blot 和免疫组化染色来检查 c-kit、SCF、胰蛋白酶、TGF-β、Wnt 和α-SMA 的表达。膀胱压力和容量试验的结果表明,CP 大鼠的膀胱最大容量、残余尿量和最大排空量显著增加。CP 大鼠的逼尿肌中胶原沉积明显增加。H&E 染色显示 CP 大鼠的逼尿肌排列紊乱,有断裂。Western blot 和免疫组化染色的结果表明,CP 组膀胱逼尿肌中的 c-kit/SCF 和 TGF-β/Wnt/β-catenin 通路活性、胰蛋白酶和α-SMA 的表达水平与对照组相比显著增加。然而,白藜芦醇治疗显著改善了这些因素。CP 大鼠中 c-kit/SCF 表达增加引起的肥大细胞激活,可能促进与尿功能障碍密切相关的逼尿肌纤维化。白藜芦醇可以通过下调肥大细胞激活和 TGF-β/Wnt/β-catenin 通路活性来改善功能障碍。